Novo Nordisk Sues Sun Pharma, Alkem to Block Semaglutide Generics

• Novo Nordisk has sued Sun Pharma and Alkem Laboratories in Delhi High Court over alleged patent infringement of its weight-loss drug semaglutide (Wegovy).
• The lawsuits aim to prevent Sun Pharma and Alkem from manufacturing or selling semaglutide or its derivatives.
• This legal action follows a previous case where Dr. Reddy's Laboratories was allowed to manufacture and export semaglutide but prohibited from domestic sales.
• Novo Nordisk holds two key Indian patents for semaglutide: one for composition (expired Sept 2024) and another for formulations/delivery devices (valid until March 2026).
• The outcome of these cases will significantly impact generic entry into India's growing market for GLP-1 drugs, especially for obesity and diabetes treatments.

Why It Matters: It determines when generic versions of a popular weight-loss drug reach India.